Immunomodulatory effects of BXL-01-0029, a less hypercalcemic vitamin D analogue, in human cardiomyocytes and T cells

Experimental Cell Research

Volumn 315, Issue 2, 2009, Pages 264-273

  Sottili, M ^a   Cosmi, L ^a   Borgogni, E ^a   Sarchielli, E ^a   Maggi, L ^a   Francalanci, M ^a   Vannelli, G B ^a   Ronconi, E ^a   Adorini, L ^b   Annunziato, F ^a   Romagnani, P ^a   Serio, M ^a   Crescioli, C ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BioXell SpA   (Italy)

Author keywords

CXCL10; Heart transplantation; Immunosuppression; Mycophenolic acid; Vitamin D analogue

Indexed keywords

BXL 01 0029; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYCOPHENOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG POTENCY; FETUS; GENE EXPRESSION; GRAFT FAILURE; GRAFT REJECTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; PRIORITY JOURNAL;

EID: 57749205602     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.10.025     Document Type: Article

References (45)

1. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351 (2004) 2715-2729
2. Lindenfeld J., Miller G.G., Shakar S.F., Zolty R., Lowes B.D., Wolfel E.E., Mestroni L., II Page R.L., and Kobashigawa J. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 110 (2004) 3734-3740
3. Tellides G. Th1 adaptive immune responses in cardiac graft arteriosclerosis: deleterious or beneficial?. Circulation 114 (2006) 1561-1564
4. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., and Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J. Exp. Med. 193 (2001) 975-980
5. Haskova Z., Izawa A., Contreras A.G., Flynn E., Boulday G., and Briscoe D.M. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 83 (2007) 1595-1601
6. Crescioli C., Squecco R., Cosmi L., Sottili M., Gelmini S., Borgogni E., Sarchielli E., Scolletta S., Francini F., Annunziato F., Vannelli G.B., and Serio M. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp. Cell Res. 314 (2008) 1337-1350
7. C. Crescioli, A. Buonamano, S. Scolletta, M. Sottili, M. Francalanci, P. Giomarelli, B. Biagioli, G. Lisi, F. Pradella, M. Serio, P. Romagnani, M. Maccheroni, Predictive role of pre-transplant serum CXCL10 for cardiac acute rejection, Transplantation in press.
8. Rotondi M., Rosati A., Buonamano A., Lasagni L., Lazzeri E., Pradella F., Fossombroni V., Cirami C., Liotta F., La Villa G., Serio M., Bertoni E., Salvadori M., and Romagnani P. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am. J. Transp. 4 (2004) 1466-1474
9. Lazzeri E., Rotondi M., Mazzinghi B., Lasagni L., Buonamano A., Rosati A., Pradella F., Fossombroni V., La Villa G., Gacci M., Bertoni E., Serio M., Salvadori M., and Romagnani P. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 79 (2005) 1215-1220
10. van Etten E., Branisteanu D.D., Verstuyf A., Waer M., Bouillon R., and Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 69 (2000) 1932-1942
11. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167 (2001) 1945-1953
12. Adorini L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs 3 (2002) 1458-1463
13. Amuchastegui S., Daniel K.C., and Adorini L. Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 80 (2005) 81-87
14. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51 (2002) 1367-1374
15. Uskokovic M.R., Norman A.W., Manchand P.S., Studzinski G.P., Campbell M.J., Koeffler H.P., Takeuchi A., Siu-Caldera M., Rao D.S., and Reddy G.S. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 66 (2001) 463-471
16. Fichera A., Little N., Dougherty U., Mustafi R., Cerda S., Li Y.C., Delgado J., Arora A., Campbell L.K., Joseph L., Hart J., Noffsinger A., and Bissonnette M. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J. Surg. Res. 142 (2007) 239-245
17. Borgogni E., Sarchielli E., Sottili M., Santarlasci V., Cosmi L., Gelmini S., Lombardi A., Cantini G., Perigli G., Luconi M., Vannelli G.B., Annunziato F., Adorini L., Serio M., and Crescioli C. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology 149 (2008) 3626-3634
18. Maggi L., Santarlasci V., Liotta F., Frosali F., Angeli R., Cosmi L., Maggi E., Romagnani S., and Annunziato F. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ Tregulatory cells in both nonatopic and atopic individuals. J. Allergy Clin. Immunol. 120 (2007) 429-436
19. Crescioli C., Cosmi L., Borgogni E., Santarlasci V., Gelmini S., Sottili M., Sarchielli E., Mazzinghi B., Francalanci M., Pezzatini A., Perigli G., Vannelli G.B., Annunziato F., and Serio M. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J. Endocrinol. 195 (2007) 145-155
20. Cosmi L., Annunziato F., Galli G., Maggi E., Nagata K., and Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30 (2000) 2972-2979
21. De Lean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-E102
22. Kobashigawa J.A., and Patel J.K. Immunosuppression for heart transplantation: where are we now?. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006) 203-212
23. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., Hancock W.W., and Briscoe D.M. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104 (2001) 2558-2564
24. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., and Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J. Immunol. 169 (2002) 1556-1560
25. Fahmy N.M., Yamani M.H., Starling R.C., Ratliff N.B., Young J.B., McCarthy P.M., Feng J., Novick A.C., and Fairchild R.L. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 75 (2003) 2044-2047
26. Fahmy N.M., Yamani M.H., Starling R.C., Ratliff N.B., Young J.B., McCarthy P.M., Feng J., Novick A.C., and Fairchild R.L. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 75 (2003) 72-78
27. Zhu J., Xu Z.K., Miao Y., Liu X.L., and Zhang H. Changes of inducible protein-10 and regulated upon activation, normal T cell expressed and secreted protein in acute rejection of pancreas transplantation in rats. World J. Gastroenterol. 12 (2006) 4156-4160
28. Campbell J.D., Gangur V., Simons F.E., and HayGlass K.T. Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J. 18 (2004) 329-331
29. Wang X., Yue T.L., Ohlstein E.H., Sung C.P., and Feuerstein G.Z. Interferonγ-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J. Biol. Chem. 271 (1996) 24286-24293
30. Romagnani P., Beltrame C., Annunziato F., Lasagni L., Luconi M., Galli G., Cosmi L., Maggi E., Salvadori M., Pupilli C., and Serio M. Role for interactions between IP-10/Mig and their receptor (CXCR3) in proliferative glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 2518-2526
31. Romagnani P., Lazzeri E., Lasagni L., Mavilia C., Beltrame C., Francalanci M., Rotondi M., Annunziato F., Maurenzig L., Cosmi L., Galli G., Salvadori M., Maggi E., and Serio M. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J. Am. Soc. Nephrol. 13 (2002) 53-64
32. Bonacchi A., Romagnani P., Romanelli R.G., Efsen E., Annunziato F., Lasagni L., Francalanci M., Serio M., Laffi G., Pinzani M., Gentilini P., and Marra F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276 (2001) 9945-9954
33. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., Uguccioni M., Galli G., Cosmi L., Maurenzig L., Baggiolini M., Maggi E., Romagnani S., and Serio M. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107 (2001) 53-63
34. Romagnani P., Lasagni L., Annunziato F., Serio M., and Romagnani S. CXC chemokines the regulatory link between inflammation and angiogenesis. Trends Immunol. 25 (2004) 201-209
35. Lazzeri E., and Romagnani P. CXCR3-binding chemokines: multifaceted therapeutic targets. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5 (2005) 109-118
36. Adorini L., and Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. (2008) electronic publication ahead of print
37. Becker B.N., Hullett D.A., O'Herrin J.K., Malin G., Sollinger H.W., and DeLuca H. Vitamin D as immunomodulatory therapy for kidney transplantation. Transplantation 74 (2002) 1204-1206
38. Johnsson C., Binderup L., and Tufveson G. The effects of combined treatment with the novel vitamin D analogue MC 1288 and cyclosporine A on cardiac allograft survival. Transpl. Immunol. 3 (1995) 245-250
39. Hullett D.A., Cantorna M.T., Redaelli C., Humpal-Winter J., Hayes C.E., Sollinger H.W., and DeLuca H.F. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 66 (1998) 824-828
40. Redaelli C.A., Wagner M., Tien Y.H., Mazzucchelli L., Stahel P.F., Schilling M.K., and Dufour J.F. 1alpha,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 34 (2001) 926-934
41. Smith E.A., Frankenburg E.P., Goldstein S.A., Koshizuka K., Elstner E., Said J., Kubota T., Uskokovic M., and Koeffler H.P. Effects of long-term administration of vitamin D3 analogs to mice. J. Endocrinol. 165 (2000) 163-172
42. Adorini L., Penna G., Giarratana N., and Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft ejection and autoimmune diseases. J. Cell. Biochem. 88 (2003) 227-233
43. Adorini L., Amuchastegui S., Corsiero E., Laverny G., Le Meur T., and Penna G. Vitamin D receptor agonists as anti-inflammatory agents. Expert Rev. Clin. Immunol. 3 (2007) 477-489
44. Giarratana N., Penna G., Amuchastegui S., Mariani R., Daniel K.C., and Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 173 (2004) 2280-2287
45. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27 (1996) 1201-1206